Singapore-based private equity firm RRJ Capital has reportedly invested US$50 million in Triplex International Biosciences, a Chinese manufacturer of pharmaceutical products. Triplex manufactures products that can detect Hepatitis B and C, as well as certain cancers from blood and tissue samples. RRJ Capital is reportedly raising its second Asia-focused private equity fund, targeting US$5 billion in commitments.